Dear Community Member,
Finally, the weather matches what I consider summer to be - hot and warm. But not only the weather is hot and warm. Also, the stock market shows some interesting upward movements.
Did you read that Jennifer Doudna‘s company Intellia successfully proved that Gene Editing works well in humans? -Right after this promising news, the company closed a 690 million dollar financing round.
While I read through quarterly reports, I came across Moderna‘s latest result. Thanks to the global SARS CoV 2 needs of vaccine, the company reports a cash position of 5 billion dollars.
On top of that, the Biden administration announced to invest 3 billion dollars in the development of antiviral therapeutics against SARS CoV 2.
With all the money flowing towards the Life Science Industry, it looks like we get a great start into this new decade. Maybe it will be another golden age of life science that will help bring the world‘s healthcare system to the next level and cure many diseases. Or at least convert them into well manageable ones.
I am proud that we can make a small contribution to the world of tech with our podcast. Also, for the coming months, I got another round of amazing speakers willing to share their views and expertise with the community.
The detailed program to each episode will follow in the coming days:
July 9 - 11:30 am CET - Wolfgang Kienreich - An Introduction to Know Center - How Artificial Intelligence will Change the World.
July 16 - 10:00 am CET - Sebastien Groyer - 7 Tales from 20 years of Deep Tech Life Science Venture Capital Investment.
August 6 - 11:00 am CET - Kurt Höller - EIT Health (Working Titel)
The LSG2G Team started preparing the recordings; more information will follow on our Community Platform, Social Media, and Newsletter in the coming days.
Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2021 Peripheral Nerve Society Annual Meeting Read more…
Intellia Therapeutics Announces Closing of $690 Million Public Offering of Common Stock Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced today the closing of an underwritten public offering of 4,758,620 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 620,689 shares, at the public offering price of $145.00 per share. The gross proceeds raised in the offering, before underwriting discounts and commissions and estimated expenses of the offering, were approximately $690 million. Read more…
The Impact of Artificial Intelligence on CT Imaging Why new image processing tools hold promise to dramatically benefit radiology Read more…
This podcast episode will discuss the EU’s next framework program for research and innovation, Horizon Europe, and the exciting opportunities this program offers businesses, scientists, and investors. With the launch of the Horizon Europe program just weeks away, we will share insight into the program's novelties, where to start, and tips on how to be successful.
The Podcast Host, guests Kimberly Cornfield and Michael Browne will discuss questions like:
What is new in Horizon Europe? The European Innovation Council, Missions and Clusters – all you need to know
Funding for DeepTech? The opportunities for high-risk/high gain and interdisciplinary research and innovation collaboration
Where, when, and how to apply for Horizon Europe funding? – tips from the experts
We shall address all these questions and discuss the latest EU research and innovation funding priorities and the importance of collaboration.
Our guests in this episode:
Kimberly Cornfield is Head of European Research and Innovation at University College London (UCL), one of the top-performing universities under the EU’s Horizon 2020 program, having secured ca. €400 million over the last seven years to support its research and innovation activities. To support UCL in upholding its place as one of the leading universities in the next EU research and innovation program, Horizon Europe, and achieving its impact objectives, Kimberly and her team connect scientists and businesses around EU collaborative funding opportunities and offer a suite of support services to improve the chances of success in obtaining funding and achieving their impact objectives.
Michael Browne is Director and Co-founder at Crowdhelix - an Open Innovation Platform that forges links between an international network of excellent researchers and innovating companies to help deliver pioneering collaborative projects. Michael has worked in the European Research & Innovation space for more than 15 years and is a recognized expert in Framework Programme funding.
These companies make the community, this newsletter, and the LSG2G Podcast possible, so go check them out and thank them for their support!
You are receiving the LSG2G-Letter because you either signed up or attended one of the events organized by LSG2G. Feel free to unsubscribe if you aren’t finding this valuable.
Nothing in this email is intended to serve as financial advice. Do your own research.